Enhanced phagocytic activity of HIV-specific antibodies correlates with natural production of immunoglobulins with skewed affinity for FcγR2a and FcγR2b. - Wikidata - awgldk - TriplyDB

Enhanced phagocytic activity of HIV-specific antibodies correlates with natural production of immunoglobulins with skewed affinity for FcγR2a and FcγR2b.

Enhanced phagocytic activity of HIV-specific antibodies correlates with natural production of immunoglobulins with skewed affinity for FcγR2a and FcγR2b.

http://www.wikidata.org/entity/Q40529181

about

Cell-targeting antibodies in immunity to Ebola Systems serology for evaluation of HIV vaccine trials.Dimeric FcγR Ectodomains as Probes of the Fc Receptor Function of Anti-Influenza Virus IgG.Production of IgG antibodies to pneumococcal polysaccharides is associated with expansion of ICOS+ circulating memory T follicular-helper cells which is impaired by HIV infection.Which Antibody Functions are Important for an HIV Vaccine?Polymorphisms and interspecies differences of the activating and inhibitory FcγRII of Macaca nemestrina influence the binding of human IgG subclasses.Antiviral Functions of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific IgG Antibodies: Effects of Antiretroviral Therapy and Implications for Therapeutic HIV-1 Vaccine Design.New paradigms for functional HIV-specific nonneutralizing antibodies Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication.Short communication: Fc gamma receptors IIa and IIIa genetic polymorphisms do not predict HIV-1 disease progression in Kenyan women.Prospects for engineering HIV-specific antibodies for enhanced effector function and half-life.Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function.Viremic HIV Controllers Exhibit High Plasmacytoid Dendritic Cell-Reactive Opsonophagocytic IgG Antibody Responses against HIV-1 p24 Associated with Greater Antibody Isotype Diversification.Isotype Diversification of IgG Antibodies to HIV Gag Proteins as a Therapeutic Vaccination Strategy for HIV Infection.Polyfunctional HIV-Specific Antibody Responses Are Associated with Spontaneous HIV Control.Expression Profile of Human Fc Receptors in Mucosal Tissue: Implications for Antibody-Dependent Cellular Effector Functions Targeting HIV-1 Transmission.Discrete partitioning of HIV-1 Env forms revealed by viral capture.Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and Subclasses A Bivalent, Chimeric Rabies Virus Expressing Simian Immunodeficiency Virus Envelope Induces Multifunctional Antibody Responses.Networking at the level of host immunity: immune cell interactions during persistent viral infections B-cell-independent sialylation of IgG.Opportunities to exploit non-neutralizing HIV-specific antibody activity.The role of Fc receptors in HIV prevention and therapy.A method for high-throughput, sensitive analysis of IgG Fc and Fab glycosylation by capillary electrophoresis Fc Receptor-Mediated Activities of Env-Specific Human Monoclonal Antibodies Generated from Volunteers Receiving the DNA Prime-Protein Boost HIV Vaccine DP6-001 Divergent antibody subclass and specificity profiles but not protective HLA-B alleles are associated with variable antibody effector function among HIV-1 controllers.Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles.Systemic and topical use of monoclonal antibodies to prevent the sexual transmission of HIV.Engineering broadly neutralizing antibodies for HIV prevention and therapy.Diversity of Antiviral IgG Effector Activities Observed in HIV-Infected and Vaccinated Subjects.HIV-specific antibody-dependent phagocytosis matures during HIV infection.Antibody Functional Assays as Measures of Fc Receptor-Mediated Immunity to HIV - New Technologies and their Impact on the HIV Vaccine Field.Temporal variation in HIV-specific IgG subclass Abs during acute infection differentiates spontaneous controllers from chronic progressors.The direct and indirect effects of glycans on immune function.Non-Neutralizing Antibodies Directed against HIV and Their Functions.HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies.High-resolution definition of humoral immune response correlates of effective immunity against HIV.

P2860

Q28068972-80D9707E-83B7-4AC8-8B8D-3D5A9370BACB Q30238729-9E73E633-6D89-499E-8C73-AF8F12F49E24 Q30390233-E09EC37A-9F38-4C5B-B4A3-D38420D3B312 Q33626626-F0D52D70-8AE1-41A3-937D-98B1881F6662 Q33772637-CB61E2F5-C62F-4E68-9C81-6BC288B8991B Q33842408-EB910E06-FB21-427E-BCE8-DB61E3C45642 Q33867299-262BDA5B-26F5-49D9-B53A-C883B622CA24 Q33900595-89552E4D-AAAB-47F7-BAFF-A53F903B5730 Q34204325-BE7222F4-E799-48C6-9B6A-D38E04BEAB19 Q34869927-2305167C-D9AD-4453-97D6-4F9DA816AAD2 Q35142518-F2CFD809-567F-4D51-BF9F-57A90418CA92 Q35569901-98648E9A-6EFF-42ED-8167-09D0248F15FC Q35600028-3E6F0E06-427A-4B81-82E8-19C69900BD28 Q35823060-E381B2B7-0AAC-4CA1-BECB-4FA619BD1F75 Q35826668-F0B4B39C-9ABD-472F-BF7C-8F9BCF8D9DA7 Q35888710-6BE11000-4C6A-4BE0-BB54-4C49D8070ADD Q36013396-AB68E4B7-6D24-49EF-AD57-CD5A14ED290B Q36088254-7D808F10-22EB-4405-8B74-D8B45C191E68 Q36118373-01DB3350-788F-48D8-BF7E-B890A74F308B Q36294739-C0B88A2A-A318-45EC-8451-4E3670F93AF2 Q37020616-731629FA-8370-4D41-BAB0-54EAB156DC4C Q37065114-2F439B91-EB72-4311-B0C8-12C9E77D89D6 Q37113941-C026AAEF-0073-435F-9600-65036D8CE1C8 Q37113972-CA52DD35-D8F2-452C-8B31-ED65EA51A191 Q37319976-A265A9D2-263B-4806-B175-FB23C90F2507 Q37409262-44E6135F-B501-4632-B6EE-33B51D652C43 Q37643973-0DCA1AC9-BFC4-4BFF-B677-6C00485BB930 Q37677278-1562F1D5-7BEE-4E38-BFF0-77FEBFA6868A Q38688524-733912EA-4AFE-4606-B01F-2E2E8FD7322D Q38717198-00821F6B-4039-467F-9082-586B3561DF64 Q38727815-3DB0832A-D056-4E03-9201-B1B5E5FE7BAA Q38873975-933F9619-6544-476C-80D3-B94396289BD6 Q39189458-F0FD605A-9106-46DC-9F87-CC8798570B31 Q46632788-7FB2644F-97C4-40BD-8EBF-20B2C5243072 Q46632825-D3813C91-756B-4349-BC77-298C37322366 Q47139556-74F72AA0-A07C-433A-8EE6-E5E12CCA8256 Q52598776-AF9A93FD-6618-4247-AC78-EB5086261D40 Q55022148-32D85D4C-768F-4B48-ABB6-2D0072AF55A0

P2860

Enhanced phagocytic activity of HIV-specific antibodies correlates with natural production of immunoglobulins with skewed affinity for FcγR2a and FcγR2b.

http://www.wikidata.org/entity/Q40529181

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Enhanced phagocytic activity o ...... ffinity for FcγR2a and FcγR2b.

@en

type

label

Enhanced phagocytic activity o ...... ffinity for FcγR2a and FcγR2b.

@en

prefLabel

Enhanced phagocytic activity o ...... ffinity for FcγR2a and FcγR2b.

@en

P1433

Q40529181-41D8AE8D-6661-4018-BA9B-05A10D340996

P1476

Q40529181-35BC9503-777A-4006-A021-78A2EF604ED7

P2093

Q40529181-87D605BA-A5D1-4096-A520-A5A1AC8A027E

Q40529181-8D2214D6-D408-4BB0-A402-3B1A857A17FA

Q40529181-8FFCED79-18F2-4E66-853C-3DCC2FEA4B31

Q40529181-AD046387-B168-49B7-91C3-CD2AAA399B52

Q40529181-D53DDDA0-E608-4ACD-935C-BC301E1BC962

Q40529181-E4333855-D79B-4353-8D4E-E704EC34510A

Q40529181-EB9E4C87-74D7-4EE0-BDC9-3500BBDC910F

P2860

Q40529181-02EDC3ED-BFFB-4547-9A6C-CE493237B280

Q40529181-0B1BE02D-46A6-4C91-BF0A-DB79AF7F1C5C

Q40529181-13921A5C-3BA1-4740-9487-510C27CB4329

Q40529181-14EBC9C5-4B61-4E72-ADF2-84895A2D9098

Q40529181-1887D44D-BF35-436F-8489-CDED340CF4AF

Q40529181-25D7A049-2271-42CB-B15A-22562CF80901

Q40529181-2EECCB50-BFEA-434A-9CB9-32DD3CA55AA0

Q40529181-2F0F2041-CB73-46E7-83FA-2688BCB7C81D

Q40529181-30BC0419-E778-4AA9-B9BE-46F6B5175FB2

Q40529181-3340E5B5-147E-4910-B200-550184A8A3C3

P304

Q40529181-2B1A9689-9D6E-4C93-B900-2E35E5C44066

P31

Q40529181-B2F2C9F5-0B49-432F-B1DB-98D41DF88771

P356

Q40529181-16B2FB74-6DCE-406F-B229-BB2535F6BA39

P407

Q40529181-E0B521A1-A043-4561-9A4C-E5A48A1418AC

P433

Q40529181-111D2164-823E-43E2-9AF4-4E2ED72C83CC

P478

Q40529181-C655BF75-4AA1-423F-97BF-3A1DE4D600D9

P577

Q40529181-5CF4DB28-58F6-47A9-B0D7-F871C2904A9A

P698

Q40529181-F4EEE01D-2BF9-4995-BB4C-0A0D1FA3E3E8

P921

Q40529181-7411BD7A-15AB-42AC-8C51-EFB1BC5C972A

P932

Q40529181-128B0CE4-782B-4771-87CA-5B74364E524B

P356

P1433

Journal of Virology

P1476

Enhanced phagocytic activity o ...... ffinity for FcγR2a and FcγR2b.

@en

P2093

Anna F Licht

http://www.w3.org/2001/XMLSchema#string

Anne-Sophie Dugast

http://www.w3.org/2001/XMLSchema#string

Darrell J Irvine

http://www.w3.org/2001/XMLSchema#string

Elizabeth G McAndrew

http://www.w3.org/2001/XMLSchema#string

Galit Alter

http://www.w3.org/2001/XMLSchema#string

Margaret E Ackerman

http://www.w3.org/2001/XMLSchema#string

Stephen Tsoukas

http://www.w3.org/2001/XMLSchema#string

P2860

Human MO subsets as defined by expression of CD64 and CD16 differ in phagocytic activity and generation of oxygen intermediates

Fc gamma receptor type III (CD16) is included in the zeta NK receptor complex expressed by human natural killer cells

Monoclonal antibodies capable of discriminating the human inhibitory Fcgamma-receptor IIB (CD32B) from the activating Fcgamma-receptor IIA (CD32A): biochemical, biological and functional characterization

Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells

High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples

Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples

Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity.

Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor.

P304

5468-5476

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.03403-12

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

87

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23468489

http://www.w3.org/2001/XMLSchema#string

P921

P932

3648186

http://www.w3.org/2001/XMLSchema#string